The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined. METHODS: We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing of samples obtained at diagnosis. Children with known very-high-risk ALL subtypes (i.e., BCR-ABL1-positive ALL, hypodiploid ALL, and ALL in infants) were excluded from this cohort. A copy-number abnormality was identified as a predictor of poor outcome, and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL. RESULTS: More than 50 recurring copy-number abnormalities were identified, most commonly involving genes that encode regulators of B-cell development (in 66.8% of patients in the original cohort); PAX5 was involved in 31.7% and IKZF1 in 28.6% of patients. Using copy-number abnormalities, we identified a predictor of poor outcome that was validated in the independent validation cohort. This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes, and it was similar to the signature of BCR-ABL1-positive ALL, another high-risk subtype of ALL with a high frequency of IKZF1 deletion. CONCLUSIONS: Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In mice, both Ikzf1 and Ikzf3 are required for normal T cell development and maintenance of mature T cell populations88,89”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Self-citationBCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
Self-citationThe ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Self-citationPrediction by Supervised Principal Components
Bair, E., Hastie, T. J., Paul, D., & Tibshirani, R. J. (2006) · Journal of the American Statistical Association · doi:10.1198/016214505000000628 · Cited by 824
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Self-citationOn testing the significance of sets of genes
Efron, B., & Tibshirani, R. J. (2007) · The Annals of Applied Statistics · doi:10.1214/07-aoas101 · Cited by 785
Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data
Bair, E., & Tibshirani, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020108 · Cited by 749
Flagged first, then by citations
Research works printed but not linked: 3
- Shuster JJ, 1999, Cancer Res Ther Control, 9, 101
- Pui CH, 2006, Ann Hematol, 85, 88
- Mirebeau D, 2006, Haematologica, 91, 881
Cited by
Sorted by citations
Items 301–400 of 1,000
Single cell derived mRNA signals across human kidney tumors
Young, M. D., Mitchell, T. J., Custers, L., Margaritis, T., Morales-Rodriguez, F., Kwakwa, K., Khabirova, E., Kildisiute, G., Oliver, T. R. W., de Krijger, R. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23949-5 · Cited by 63
Inborn errors of human IKAROS: LOF and GOF variants associated with primary immunodeficiency
Kuehn, H. S., Boast, B., & Rosenzweig, S. D. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac109 · Cited by 60
Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia.
Kastner, P., Dupuis, A., Gaub, M., Herbrecht, R., Lutz, P., & Chan, S. H. (2013) · Europe PMC (PubMed Central) · Cited by 60
TKI dasatinib monotherapy for a patient with Ph‐like ALL bearing ATF7IP/PDGFRB translocation
Kobayashi, K., Miyagawa, N., Mitsui, K., Matsuoka, M., Kojima, Y., Takahashi, H., Otsubo, K., Nagai, J., Ueno, H., Ishibashi, T., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25327 · Cited by 60
Yang, Y., Hung, C., Chen, J., Lin, K., Jou, S., Hsiao, C., Sheen, J., Cheng, C., Wu, K., Lin, S., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02031.x · Cited by 60
Self-citationHigh BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia
Kühnl, A., Gökbuget, N., Stroux, A., Burmeister, T., Neumann, M., Heesch, S., Haferlach, T., Hoelzer, D. F., Hofmann, W., Thiel, E., et al. (2010) · Blood · doi:10.1182/blood-2009-09-241943 · Cited by 60
High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?
Pulsipher, M. A., Peters, C., & Pui, C. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.10.005 · Cited by 60
Self-citationRecurrent deletions of IKZF1 in pediatric acute myeloid leukemia
de Rooij, J. D. E., Beuling, E., van den Heuvel‐Eibrink, M. M., Obulkasim, A., Baruchel, A., Trka, J., Reinhardt, D., Sonneveld, E., Gibson, B. E. S., Pieters, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124321 · Cited by 61
Transcription factor mutations as a cause of familial myeloid neoplasms
Churpek, J. E., & Bresnick, E. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120854 · Cited by 60
McNeer, J. L., Devidas, M., Dai, Y. E., Carroll, A. J., Heerema, N. A., Gastier, J. M., Kahwash, S. B., Borowitz, M. J., Wood, B. L., Larsen, E. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00884 · Cited by 60
Self-citationThe Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms
Zhang, J., & Zhang, S. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2640963 · Cited by 62
Self-citationMolecular markers in ALL: Clinical implications
Kimura, S., & Mullighan, C. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101193 · Cited by 63
Self-citationDuhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Włodarska, I., Michaux, L., Talmant, P., Richebourg, S., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08918.x · Cited by 61
Loh, M. L., & Mullighan, C. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1936 · Cited by 59
Self-citationVilas‐Zornoza, A., Agirre, X., Martín‐Palanco, V., Martín-Subero, J. I., José‐Eneriz, E. S., Gárate, L., Álvarez, S., Miranda, E., Rodríguez‐Otero, P., Rifón, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017012 · Cited by 58
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool
Galimberti, S., Balducci, S., Guerrini, F., Re, M. D., & Cacciola, R. R. (2022) · Diagnostics · doi:10.3390/diagnostics12061305 · Cited by 58
Iacobucci, I., Lonetti, A., Paoloni, F. P., Papayannidis, C., Ferrari, A., Storlazzi, C. T., Vignetti, M., Cilloni, D., Messa, F., Guadagnuolo, V., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.020792 · Cited by 58
Slámová, L., Starková, J., Froňková, E., Zaliova, M. K., Reznickova, L. R., van Delft, F. W., Vodickova, E., Volejníková, J., Zemanová, Z., Polgárová, K., et al. (2013) · Leukemia · doi:10.1038/leu.2013.354 · Cited by 57
Suryani, S., Bracken, L. S., Harvey, R. C., Sia, K. C. S., Carol, H., Chen, I., Evans, K., Dietrich, P. A., Roberts, K. G., Kurmasheva, R. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0647 · Cited by 57
Self-citationGuidelines for genomic array analysis in acquired haematological neoplastic disorders
Schoumans, J., Suela, J., Hastings, R. J., Müehlematter, D., Rack, K. A., van den Berg, E., Beverloo, H. B., & Stevens‐Kroef, M. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22350 · Cited by 57
Targeting the mTOR Pathway in Leukemia
Dinner, S. N., & Platanias, L. C. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25559 · Cited by 57
Wang, H., Song, C., Ding, Y., Pan, X., Ge, Z., Tan, B., Gowda, C. S., Sachdev, M., Muthusami, S., Ouyang, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679332 · Cited by 56
Griffith, M., Griffith, O. L., Krysiak, K., Skidmore, Z. L., Christopher, M. J., Klco, J. M., Ramu, A., Westover, T., Wagner, A. H., Campbell, K. M., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.04.011 · Cited by 56
Self-citationScheijen, B., Boer, J. M., Marke, R., Tijchon, E. J. H., Schenau, D. V. I., Waanders, E., van Emst, L., van der Meer, L. T., Pieters, R., Escherich, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.153023 · Cited by 56
Steeghs, E. M. P., Boer, J. M., Hoogkamer, A. Q., Boeree, A., de Haas, V., de Groot‐Kruseman, H. A., Horstmann, M. A., Escherich, G., Pieters, R., & den Boer, M. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-41078-4 · Cited by 56
Eskandarian, Z., Fliegauf, M., Bulashevska, A., Proietti, M., Hague, R., Smulski, C. R., Schubert, D., Warnatz, K., & Grimbacher, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00568 · Cited by 56
Genome-wide arrays in routine diagnostics of hematological malignancies
Simons, A., Sikkema‐Raddatz, B., de Leeuw, N., Konrad, N. C., Hastings, R. J., & Schoumans, J. (2012) · Human Mutation · doi:10.1002/humu.22057 · Cited by 55
Okamoto, R., Ogawa, S., Nowak, D., Kawamata, N., Akagi, T., Kato, M., Sanada, M., Weiss, T., Haferlach, C., Dugas, M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.011114 · Cited by 55
Genomic profiling of B-progenitor acute lymphoblastic leukemia
Mullighan, C. G. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.09.004 · Cited by 57
Self-citationGenomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
Vesely, C., Frech, C., Eckert, C., Cario, G., Mecklenbräuker, A., Stadt, U. Z., Nebral, K., Kraler, F. A.-M., Fischer, S. H., Attarbaschi, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.365 · Cited by 55
Dense time-course gene expression profiling of the Drosophila melanogaster innate immune response
Schlamp, F., Delbare, S., Early, A. M., Wells, M. T., Basu, S., & Clark, A. G. (2021) · BMC Genomics · doi:10.1186/s12864-021-07593-3 · Cited by 54
Ikaros, CK2 kinase, and the road to leukemia
Dovat, S., Song, C., Payne, K. J., & Li, Z. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0964-5 · Cited by 54
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia
Song, C., Pan, X., Ge, Z., Gowda, C. D. R., Ding, Y., Li, H., Li, Z., Yochum, G. S., Müschen, M., Li, Q., et al. (2015) · Leukemia · doi:10.1038/leu.2015.331 · Cited by 54
A high-resolution map of transcriptional repression
Liang, Z., Brown, K. E., Carroll, T., Taylor, B., Vidal, I. F., Hendrich, B., Rueda, D., Fisher, A. G., & Merkenschlager, M. (2017) · eLife · doi:10.7554/elife.22767 · Cited by 54
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
Cario, G., Leoni, V., Conter, V., Baruchel, A., Schrappe, M., & Biondi, A. (2020) · Haematologica · doi:10.3324/haematol.2018.207019 · Cited by 53
Ribera, J., Morgades, M., Zamora, L., Montesinos, P., Gómez‐Seguí, I., Pratcorona, M., Sarrà, J., Guàrdia, R., Nomdedéu, J., Tormo, M., et al. (2015) · Cancer · doi:10.1002/cncr.29579 · Cited by 53
Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments
Iacobucci, I., Papayannidis, C., Lonetti, A., Ferrari, A., Baccarani, M., & Martinelli, G. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0122-5 · Cited by 56
The biology of Philadelphia chromosome-like ALL
Roberts, K. G. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.07.003 · Cited by 53
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi, M., & Litzow, M. R. (2018) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s170351 · Cited by 53
Javierre, B. M., Rodríguez‐Ubreva, J., Al‐Shahrour, F., Corominas, M., Graña‐Castro, O., Ciudad, L., Agirre, X., Pisano, D. G., Valencia, A., Román‐Gómez, J., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0515 · Cited by 52
Öfverholm, I. I., Tran, A. N., Heyman, M. M., Zachariadis, V., Nordenskjöld, M., Nordgren, A., & Barbany, G. (2013) · Leukemia · doi:10.1038/leu.2013.92 · Cited by 51
Mullighan, C. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1203 · Cited by 51
Self-citationBCR-ABL1 -like acute lymphoblastic leukaemia: From bench to bedside
Boer, J. M., & den Boer, M. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.012 · Cited by 51
Emerging Opportunities for Target Discovery in Rare Cancers
Sharifnia, T., Hong, A. L., Painter, C., & Boehm, J. S. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.002 · Cited by 51
Precision medicine in pediatric oncology
Burdach, S. E. G., Westhoff, M., Steinhauser, M., & Debatin, K. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0084-3 · Cited by 53
Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia
Heikamp, E., & Pui, C. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.07.039 · Cited by 51
Self-citationBCR-ABL1–like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review
Jain, S., & Abraham, A. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0194-ra · Cited by 51
Kimura, S., Montefiori, L. E., Iacobucci, I., Zhao, Y., Gao, Q., Paietta, E. M., Haferlach, C., Laird, A., Mead, P. E., Gu, Z., et al. (2022) · Blood · doi:10.1182/blood.2022015444 · Cited by 53
Self-citationWang, J., Mi, J., Debernardi, A., Vitte, A.-L., Emadali, A., Meyer, J. A., Charmpi, K., Ycart, B., Callanan, M. B., Carroll, W. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4113 · Cited by 50
Self-citationIllegitimate V(D)J recombination involving nonantigen receptor loci in lymphoid malignancy
Onozawa, M., & Aplan, P. D. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21942 · Cited by 50
Bokemeyer, A., Eckert, C., Meyr, F., Körner, G., von Stackelberg, A., Ullmann, R., Türkmen, S., Henze, G., & Seeger, K. (2013) · Haematologica · doi:10.3324/haematol.2012.072470 · Cited by 50
Targeting signaling pathways in acute lymphoblastic leukemia: new insights
Harrison, C. J. (2013) · Hematology · doi:10.1182/asheducation-2013.1.118 · Cited by 50
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre–B ALL
Schjerven, H., Ayongaba, E. F., Aghajanirefah, A., McLaughlin, J., Cheng, D., Geng, H., Boyd, J. R., Eggesbø, L. M., Lindeman, I., Heath, J. L., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160049 · Cited by 52
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
Takahashi, K., Inukai, T., Imamura, T., Yano, M., Tomoyasu, C., Lucas, D. M., Nemoto, A., Sato, H., Huang, M., Abe, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188680 · Cited by 50
Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?
Neaga, A., Jimbu, L., Mesaros, O., Bota, M., Lazar, D. R., Cainap, S. S., Blag, C. L., & Zdrenghea, M. (2021) · Cancers · doi:10.3390/cancers13153886 · Cited by 52
Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia
Tasian, S. K., & Loh, M. L. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.30 · Cited by 50
Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia
Campana, D. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0056-8 · Cited by 49
Self-citationForero‐Castro, M., Robledo, C., Benito, R., Abáigar, M., Martín, A. Á., Arefi, M., Fuster, J. L., Heras, N. D. L., Rodríguez, N., Quintero, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148972 · Cited by 49
Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.
Mohseni, M. M., Uludağ, H., & Brandwein, J. M. (2018) · Europe PMC (PubMed Central) · Cited by 49
JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
Steeghs, E. M. P., Jerchel, I. S., de Goffau-Nobel, W., Hoogkamer, A. Q., Boer, J. M., Boeree, A., van de Ven, C., Koudijs, M. J., Besselink, N. J. M., de Groot‐Kruseman, H. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21027 · Cited by 48
Montaño, A., Forero‐Castro, M., Marchena-Mendoza, D., Benito, R., & Hernández‐Rivas, J. M. (2018) · Cancers · doi:10.3390/cancers10040110 · Cited by 48
The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia
Algeri, M., Merli, P., Locatelli, F., & Pagliara, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173790 · Cited by 49
Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia
Li, Z., Chang, T., Junco, J. J., Devidas, M., Li, Y., Yang, W., Huang, X., Hedges, D. J., Cheng, Z., Shago, M., et al. (2023) · Blood · doi:10.1182/blood.2023019765 · Cited by 47
Self-citationB-Cell Receptor Signaling in Lymphoid Malignancies and Autoimmunity
Avalos, A. M., Meyer‐Wentrup, F. A. G., & Ploegh, H. L. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800266-7.00004-2 · Cited by 47
Genomic profiling of high-risk acute lymphoblastic leukemia
Collins-Underwood, J. R., & Mullighan, C. G. (2010) · Leukemia · doi:10.1038/leu.2010.177 · Cited by 47
Self-citationSafavi, S., Hansson, M., Karlsson, K., Biloglav, A., Johansson, B., & Paulsson, K. M. (2014) · Haematologica · doi:10.3324/haematol.2014.112912 · Cited by 47
How advanced are we in targeting novel subtypes of ALL?
Mullighan, C. G. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101095 · Cited by 47
Self-citationPAX5 alterations in B-cell acute lymphoblastic leukemia
Jia, Z., & Gu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023606 · Cited by 46
Chen, C., Bartenhagen, C., Gombert, M., Okpanyi, V., Binder, V., Röttgers, S., Bradtke, J., Teigler‐Schlegel, A., Harbott, J., Ginzel, S., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.005 · Cited by 46
Olsson, L., Öfverholm, I. I., Norén‐Nyström, U., Zachariadis, V., Nordlund, J., Sjögren, H., Golovleva, I., Nordgren, A., Paulsson, K. M., Heyman, M. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13514 · Cited by 46
Cario, G., Rhein, P., Mitlöhner, R., Zimmermann, M., Bandapalli, O. R., Romey, R., Moericke, A., Ludwig, W. D., Ratei, R., Muckenthaler, M. U., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090225 · Cited by 46
Hunger, S. P. (2011) · Hematology · doi:10.1182/asheducation-2011.1.361 · Cited by 46
Self-citationCurrent and future management of Ph/BCR-ABL positive ALL
Maino, E., Sancetta, R., Viero, P., Imbergamo, S., Scattolin, A. M., Vespignani, M., & Bassan, R. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.895669 · Cited by 46
Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
Schrappe, M. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.137.3798216 · Cited by 46
Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia
Carroll, W. L., & Raetz, E. A. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.08.006 · Cited by 46
Self-citationRisk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention
Ceppi, F., Cazzaniga, G., Colombini, A., Biondi, A., & Conter, V. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.978281 · Cited by 45
Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia
Chiaretti, S., Gianfelici, V., O'Brien, S. M., & Mullighan, C. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156628 · Cited by 45
Self-citationChurchman, M. L., & Mullighan, C. G. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.002 · Cited by 45
Self-citationCell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia
Fischer, U., Yang, J. J. J., Ikawa, T., Hein, D., Vicente‐Dueñas, C., Borkhardt, A., & Sánchez-García, I. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0011 · Cited by 48
Tran, T. H., & Tasian, S. K. (2024) · Blood · doi:10.1182/blood.2023023153 · Cited by 44
Bottardi, S., Mavoungou, L. O., Pak, H., Daou, S., Bourgoin, V., Lakehal, Y. A., Affar, E. B., & Milot, É. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004827 · Cited by 44
Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia
Jeha, S., & Pui, C. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.07.009 · Cited by 44
Self-citationLahti, L., Schäfer, M. K.-H., Klein, H., Bicciato, S., & Dugas, M. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs005 · Cited by 44
Wang, Y., Miller, S., Roulston, D., Bixby, D. L., & Shao, L. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.03.004 · Cited by 44
New targeted therapies for relapsed pediatric acute lymphoblastic leukemia
Pierro, J., Hogan, L. E., Bhatla, T., & Carroll, W. L. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1347507 · Cited by 47
Self-citationAberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia
Rahmani, M., Talebi, M., Hagh, M. F., Feizi, A. A. H., & Solali, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.033 · Cited by 44
Avigad, S., Verly, I. R. N., Lebel, A., Kordi, O., Shichrur, K., Ohali, A., Hameiri-Grossman, M., Kaspers, G. J. L., Cloos, J. J., Froňková, E., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22334 · Cited by 44
Pieters, R., de Groot‐Kruseman, H., Fiocco, M. F., Verwer, F., van Overveld, M., Sonneveld, E., van der Velden, V. H. J., Beverloo, H. B., Bierings, M., Dors, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02705 · Cited by 43
Fielding, A. K. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e352 · Cited by 44
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia
Eswaran, J., Sinclair, P. B., Heidenreich, O. T., Irving, J. A. E., Russell, L. J., Hall, A. G., Calado, D. P., Harrison, C. J., & Vormoor, J. H. (2015) · Leukemia · doi:10.1038/leu.2015.113 · Cited by 44
Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1
Song, C. (2011) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v2.i6.126 · Cited by 43
Future of Clinical Genomics in Pediatric Oncology
Janeway, K. A., Place, A. E., Kieran, M. W., & Harris, M. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8470 · Cited by 47
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Moujalled, D. M., Hanna, D. T., Hediyeh-zadeh, S., Pomilio, G., Brown, L. M., Litalien, V., Bartolo, R. C., Fleming, S. A., Chanrion, M., Banquet, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001416 · Cited by 43
Self-citationQin, P., Pang, Y., Hou, W., Fu, R., Zhang, Y., Wang, X. J., Meng, G., Liu, Q., Zhu, X., Hong, N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-020-00223-4 · Cited by 46
Kuehn, H. S., Nunes-Santos, C. J., & Rosenzweig, S. D. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00936-x · Cited by 43
Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia
Cobaleda, C., Vicente‐Dueñas, C., & Sánchez-García, I. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00505-2 · Cited by 47
Optimal false discovery rate control for dependent data
Cai, T., Li, H., Maris, J. M., & Xie, J. (2011) · Statistics and Its Interface · doi:10.4310/sii.2011.v4.n4.a1 · Cited by 45
Ambrož, M., Matoušková, P., Skarka, A., Zajdlová, M., Žáková, K., & Skálová, L. (2017) · Molecules · doi:10.3390/molecules22061021 · Cited by 43
Rudant, J., Orsi, L., Bonaventure, A., Goujon, S., Baruchel, A., Petit, A., Bertrand, Y., Nelken, B., Pasquet, M., Michel, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121348 · Cited by 42
Walter, W., Shahswar, R., Stengel, A., Meggendorfer, M., Kern, W., Haferlach, T., & Haferlach, C. (2021) · BMC Cancer · doi:10.1186/s12885-021-08635-5 · Cited by 42
Metadata
- Authors
- Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., Harvey, R. C., Chen, I.-M., Clifford, R. J., Carroll, W. L., Reaman, G., Bowman, W. P., Devidas, M., Gerhard, D. S., Yang, W., Relling, M. V., Shurtleff, S. A., Campana, D., Borowitz, M. J., Pui, C.-H., Smith, M., Hunger, S. P., Willman, C. L., & Downing, J. R.
- Affiliations
- St. Jude Children's Research Hospital (US)
- National Institutes of Health (US)
- UNM Comprehensive Cancer Center (US)
- New York University (US)
- Children's National (US)
- Cook Children's Medical Center (US)
- University of Florida Health (US)
- Children's Hospital Colorado (US)
- ORCID
- Mullighan, Charles G.
- Su, Xiaoping
- Zhang, Jinghui
- Radtke, Ina
- Ma, Jing
- Liu, Wei
- Cheng, Cheng
- Schulman, Brenda A.
- Harvey, Richard C.
- Chen, I-Ming
- Clifford, Robert J.
- Carroll, William L.
- Reaman, Gregory
- Bowman, W. Paul
- Devidas, Meenakshi
- Yang, Wenjian
- Relling, Mary V.
- Campana, Dario
- Pui, Ching-Hon
- Smith, Malcolm
- Hunger, Stephen P.
- Willman, Cheryl L.
- Downing, James R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-01-29
- Volume
- 360
- Issue
- 5
- Pages
- 470-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2674612
- OpenAlex
- W2040329520
- Cited by
- 1,422
- References
- 37
- Citations by year
- 2026: 30 · 2025: 50 · 2024: 66 · 2023: 90 · 2022: 66 · 2021: 103 · 2020: 92 · 2019: 69 · 2018: 74 · 2017: 105 · 2016: 96 · 2015: 101 · 2014: 84 · 2013: 90 · 2012: 98
- FWCI
- 101.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (N01C012400, 21765)
- National Cancer Institute (CA 098543, R01CA086011, U10CA098413, U01CA157937, R01 CA86011, U10CA098543, U01CA114762, CA114762, P30CA021765)
- National Institute of General Medical Sciences (U01 GM61393, U01GM061374, U01-GM-61374, U01GM061393)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- IKZF1 deletion, acute lymphoblastic leukemia, pediatric leukemia, copy number abnormalities, prognosis, PAX5, Ikaros, B cell development, gene expression signatures, relapse
- MeSH terms
- B-Lymphocytes, Child, DNA Mutational Analysis, Genotype, Hematopoietic Stem Cells, Humans, Prognosis, Recurrence, Cohort Studies, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Trans-Activators, Gene Expression, Treatment Outcome, Gene Deletion, Drug Resistance, Neoplasm, Mutation, Missense, Gene Expression Profiling, Ikaros Transcription Factor, PAX5 Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
